Proactive COPDPROactive COPD

Font size: Font SmallFont MediumFont Large

The PROactive Project

The results of the research performed by the PROactive consortium will be of immediate importance to the 10% of elderly European citizens suffering from COPD. It will provide a means of assessing the impact of either medication or rehabilitation by asking the patient how it has affected their everyday physical activity. This, in turn, will allow clinicians and pharmaceutical companies to reflect the outcomes and results of these interventions and treatments in the patients’ own language (the “patient reported” part).

What is the PROactive project?

COPD

The PROactive project is a European project funded by the Innovative Medicines Initiative (IMI). IMI is a Joint Initiative (JI) funded by both the EC (via the FP7 research programme) and EFPIA. Under this initiative, the PROactive consortium aims to improve care for COPD patients. The consortium includes 19 partners (academic institutions, a small-to-medium sized enterprise, patient organisations and eight major pharmaceutical companies).

The PROactive project aims to develop validation and use of patient reported outcome (PRO) tools to investigate dimensions of physical activity that are judged as being essential by patients living with COPD. A better understanding of all relevant dimensions (symptoms, distress, etc.) of physical activity that are meaningful to COPD patients will help describe the patients' experience of COPD. PROactive will be developed with input from the regulatory authorities, such as the European Medicines Agency (EMA). Once appropriately validated, PROactive will be used to evaluate the benefit of new treatments such as new medicinal products for COPD patients.

The project coordinator is Dr Caterina Brindicci of Chiesi Pharmaceuticals. Professor Thierry Troosters of Katholieke Universtiteit Leuven in Belgium will coordinate the scientific activities. The PROactive project will run for five years, and is funded by the European Commission and the Pharmaceuticals companies involved in the consortium.

For more information on the PROactive initiative please email: info@proactivecopd.com

Download
Submit Revision
Downloads
File History
Comments
loading